Alpha-1 antitrypsin deficiency panniculitis
What is alpha-1 antitrypsin deficiency disease?
Alpha-1 antitrypsin is a serine protease inhibitor. Alpha-1 antitrypsin deficiency disease is an inherited metabolic disorder in which this protein is absent or defective.
Alpha-1 antitrypsin deficiency disease most commonly presents as lung disease (emphysema) or gastrointestinal disease (liver cirrhosis). It can also rarely affect the skin.
Alpha-1 antitrypsin deficiency is abbreviated as A1AD.
What is panniculitis?
Panniculitis refers to a group of disorders that cause inflammation of the subcutaneous adipose tissue (the fat underneath the skin).
Panniculitis due to alpha-1 antitrypsin deficiency is rare.
Who gets alpha-1 antitrypsin deficiency panniculitis?
Alpha-1-antitrypsin deficiency is most prevalent in Caucasians of European and North American descent.
Males and females of any age are equally affected by the panniculitis associated with alpha-1 antitrypsin deficiency, and it can rarely arise in children.
As alpha-1-antitrypsin deficiency is under-diagnosed, the true prevalence of panniculitis due to alpha-1-antitrypsin deficiency is difficult to ascertain. One study reported panniculitis affected 0.9% of ZZ homozygotes for alpha-1-antitrypsin deficiency.
Panniculitis may be preceded by trauma. This is because an injury causes increased protease activation and a cascade of inflammatory events intended to heal the wound.
What causes alpha-1 anti trypsin deficiency?
Alpha-1-antitrypsin deficiency is usually due to a mutation on chromosome 14.
Alpha-1-antitrypsin deficiency is an autosomal co-dominant disorder, meaning that two different versions (alleles) of a gene are expressed in an individual. Each allele makes a slightly different protein. Both alleles influence the characteristics and severity of the deficiency disease.
There are over 90 known mutant alleles of the alpha-1-antitrypsin gene and they are classified into categories based on their acid starch gel mobility (F=fast, M=medium, S = slow, Z = very slow). A normal level of a variant enzyme with altered activity can also cause the clinical disease.
The genotype (a person’s genetic make up) and their combination of these genes determine the degree of the deficiency. The normal genotype is ‘MM’ has a normal level of alpha-1-antitrypsin. Patients with two ‘ZZ’ genes (homozygotes) are 85% deficient in alpha-1-antitrypsin. This type is the most commonly associated with emphysema.
Alpha-1-antitrypsin is mostly produced in the liver, and regulates several proteolytic enzymes including trypsin, elastase, chymotrypsin, factor VIII, collagenase and kallikrein. Lack of alpha-1 antitrypsin leads to increased activity of these enzymes and localised tissue destruction.
What are the clinical features of alpha-1 antitrypsin deficiency?
Deficiency of alpha 1 antitrypsin leads to inflammation and necrosis in various organs.
- Alpha-1-antitrypsin usually protects the lungs from elastase enzymes produced by neutrophils.
- When alpha 1 antitrypsin is deficient, elastase enzymes can damage and scar lung tissue causing emphysema.
- Asthma, bronchiectasis and chronic obstructive pulmonary disease are also more prevalent.
- Lung disease is much more severe in smokers than in non-smokers with alpha-1 antitrypsin deficiency.
- Abnormal alpha-1-antitrypsin protein accumulates within the liver cells (hepatocytes) and can cause hepatitis.
- Hepatitis can present with swollen abdomen, leg oedema or jaundice.
- Liver disease is accelerated by drinking alcohol.
- Later, cirrhosis (scarring of the liver) occurs.
- This increases the risk of hepatocellular carcinoma.
- Elastase is a pancreatic enzyme.
- Increased elastase due to alpha-1-antitrypsin deficiency can cause chronic pancreatitis.
- Chronic pancreatitis leads to steatorrhea, malabsorption, vitamin deficiency (A, D, E, K, B12), diabetes and weight loss.
- Membranoproliferative glomerulonephritis
In alpha-1-antitrypsin deficiency disease:
- Panniculitis is due to unopposed enzyme action and protein breakdown within the skin.
- Initially erythematous plaques and nodules develop on the trunk or proximal limbs.
- Nodules may be widespread over the legs, arms, trunk or face.
- The nodules may ulcerate, bleed and leak oily material.
- The patient may be febrile.
The panniculitis associated with alpha-1-antitrypsin deficiency disease does not improve with antibiotics or systemic steroids.
How are alpha-1-anti trypsin deficiency and associated panniculitis diagnosed?
Diagnosis of alpha-1-antitrypsin deficiency
Alpha-1-antitrypsin deficiency disease may be suspected by the clinical features, especially emphysema, chronic hepatitis and liquefying panniculitis. Several tests may be arranged to confirm the diagnosis.
Serum alpha-1-antitrypsin levels
- Serum alpha-1-antitrypsin levels can confirm if a patient is deficient or not.
- Note that alpha-1-antitrypsin can be misleadingly raised during an inflammatory state, as it is an acute phase protein.
Alpha-1-antitrypsin phenotype and genotyping
- If the disease is highly suspected and alpha-1-antitrypsin levels are normal, an iso-electrophoretic mobility study (alpha-1-antitrypsin phenotype) can be useful.
- Genotyping can detect abnormal alleles in an individual.
- Pulmonary function tests can help to establish if there is emphysema
- Chest X ray may show characteristic lung changes (emphysema at the lung bases)
- High Resolution CT (HRCT) scanning can help to identify basal emphysema and bronchiectasis
Diagnosis of panniculitis associated with alpha-1-antitrypsin deficiency
- Inflammatory markers (erythrocyte sedimentation rate and C-reactive protein) may be elevated.
- Antinuclear antibodies and rheumatoid factor may be present in low titre.
- Chronic disease can cause normocytic anaemia and hypoalbuminaemia.
Skin biopsy of panniculitis must include deep adipose tissue. Specific characteristics of alpha-1-antitrypsin deficiency panniculitis on histopathology include:
- Predominantly lobular inflammation, with some septal involvement and extensive tissue destruction.
- In early disease, neutrophils infiltrate between collagen bundles in the reticular dermis.
- The collagen in the dermis is gradually dissolved, and the epidermis can liquefy.
- The splaying of the neutrophils may progresses to involve fibrous septa and lobules of the subcutaneous fat.
- In later stages, histiocytes and lipophages are seen, sometimes with giant cell accumulation.
- Leucocytoclastic and lymphocytic vasculitis can arise in areas of dense inflammation as well as phlebothrombosis and haemmorhage.
- Skip areas of normal fat next to necrotic areas of fat can be a feature.
- Areas heal with fibrosis and sometimes, dystrophic calcification.
- Direct immunofluorescence may detect intravascular deposits of complement C3 and IgM in the dermis of uncertain significance.
What is the treatment for alpha-1-anti trypsin deficiency and its associated panniculitis?
- Avoid trauma and surgery to the area if possible
- It is essential to avoid smoking and alcohol.
- Avoid occupational exposures that may increase risk of airways disease (eg mining, construction work)
- Annual influenza vaccination is recommended
- Tetracycline antibiotics (doxycycline, minocycline) can be effective for mild panniculitis. It is thought that the anticollagenase activity of tetracyclines can help re-establish the balance between protease and antiprotease enzymes.
- Dapsone and colchicine can reduce the inflammation associated with panniculitis.
Enzyme replacement therapy
Enzyme replacement therapy with exogenous alpha-1 antitrypsin concentrate (Prolastin®) infused intravenously has been reported to be effective. The initial recommended dose of 60 mg/kg once weekly may be adjusted according to response. The dose required and duration of treatment varies according to case reports. Its use may be limited by high cost and limited availability.
- Plasma exchange
- Genetically engineered alpha-1-antitrypsin
- Organ transplantation (lungs/liver) for patients with advanced disease
What is the outcome for alpha-1-anti trypsin deficiency and its associated panniculitis?
The prognosis and life expectancy of a patient with alpha-1 antitrypsin deficiency depends on phenotype, the level of enzyme deficiency, and the associated hepatic and pulmonary damage.
Complete resolution of panniculitis associated with alpha-1-antitrypsin deficiency has been described within 4 weeks of treatment with enzyme replacement therapy. It may re occur, in which case indefinite treatment may be required.
Chronic ulceration can complicate the associated panniculitis, and when areas do finally heal they may form atrophic scarring.